FUFilippo Maria Ubaldi

Filippo Maria Ubaldi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Filippo Maria Ubaldi has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ten years of DuoStim in time-sensitive poor-prognosis IVF patients: real world cumulative outcomes and treatment trajectories

    by Filippo Maria Ubaldi, Federica Innocenti, Marilena Taggi, Silvia Colamaria, Cindy Argento, Maddalena Giuliani, Alessandro Ruffa, Erika Pittana, Chiara Gallo, Susanna Ferrero, et al.

    Aims: To evaluate DuoStim strategy across a decade from its clinical implementation in IVF by comparing embryological and clinical outcomes between the first and second ovarian stimulations (1st-OS and 2nd-OS) conducted within 30 days, focusing on treatment efficiency and time-to-conclusion. Methods: Retrospective single-center study (2015–2024) including 1656 poor-prognosis patients undergoing 1896 DuoStim cycles planned for ICSI and PGT-A at the blastocyst stage. Poor prognosis was defined as very advanced maternal age (≥40 years) and/or reduced ovarian reserve (AMH ≤1.2 ng/mL, AFC ≤5, or ≤3 oocytes in previous retrievals). Endpoints included all embryological, clinical and neonatal outcomes comparing 2nd-OS versus 1st-OS and cumulatively. Among 1561 concluded first DuoStim cycles, we calculated time-to-treatment-conclusion (TTC), stratified as without a live-birth (TTC-noLB) and with a live-birth (TTC-LB), and treatment discontinuation at our center after a first failed DuoStim attempt. Results: The use of DuoStim increased over time, reaching 34% of all cycles in 2024. The 2nd-OS yielded more oocytes and embryos than 1st-OS, while their competence was comparable. Consequently, the 2nd retrieval provided a cumulative incremental yield of 66% for cycles achieving ≥1 euploid blastocyst and 125% for cycles achieving ≥1 live birth (LB) compared with the 1st-OS alone. Median TTC was 40 days (quartile-1: 36, quartile-3: 118.5), while TTC-noLB and TTC-LB were 38 days (quartile-1: 35, quartile-3: 41.5) and 145 days (quartile-1: 112.25, quartile-3: 221), respectively. Embryological and clinical outcomes were stable across the years. Treatment discontinuation among patients without a LB after a first completed DuoStim decreased from 61% in 2015 to 44% in 2021, as second DuoStim attempts increased from 16% to 21% and transition to egg donation from 9% to 21%. Conclusion: DuoStim is a multicycle stimulation strategy that represents an alternative approach for patients requiring multiple treatment opportunities within a short timeframe. It shifts IVF toward a flexible personalized journey for poor prognosis patients. By enabling two stimulations within a single ovarian cycle, it achieved a cumulative live birth rate of 28.5% per concluded cycle in our cohort, within a consistently short timeframe in terms of both TTC-noLB and TTC-LB. Overall, DuoStim represents a treatment strategy that supports rapid and effective clinical decision-making in time-sensitive patients.


  • Open Access

    NanoCT-confocal mapping of mouse ovaries reveals lifespan-persistent symmetric organizational rules of primary-to-preovulatory follicles

    by Giulia Fiorentino, Andrea Fantinato, Annapaola Parrilli, Tommaso Marzi, Cesare Alippi, Riccardo Bellazzi, Laura Rienzi, Filippo Maria Ubaldi, Alberto Vaiarelli, Valeria Merico, et al.

    SUMMARY: Mammalian ovaries are organized into follicles integrated with the surrounding tissue, collectively shaping an architecture continuously remodeled through cycles of growth and elimination. Combining nano-Computed Tomography with 3D digital modeling, we deciphered spatial rules governing follicle organization in the mouse ovary across lifespan. We find that primary to preovulatory follicles adopt a quantitatively symmetric arrangement along the anterior-posterior and dorsal-ventral axes, established during prepuberty before secondary follicle vascularization and preserved through adulthood and aging, regardless of follicle health or atresia. A novel nanoCT-confocal pipeline revealed that follicles enclosing oocytes with transcriptionally-active or transcriptionally-inactive chromatin states follow divergent fates of growth, atresia, or developmental competence, yet retaining a symmetric distribution. Mathematical modeling of follicle growth and elimination from prepuberty to adulthood identified transition rates between follicle stages that support gonadal symmetry. These findings suggest an evolutionarily optimized developmental program ensuring follicle recruitment and high ovulatory output, a hallmark of polytocous species.

  • What protocol should not be adopted, and which patients should not be suggested double stimulation in the same ovarian cycle? A randomized controlled trial answers

    by Carlo Alviggi, Hakan Yarali, Danilo Cimadomo, Laura Rienzi, Filippo Maria Ubaldi, Alberto Vaiarelli

    Sir, We read with great interest the paper published by Boudry and colleagues entitled ‘Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial’ ( Boudry et al., 2024). The study provides additional information for evaluating unconventional stimulation protocols in IVF. It is based on 46 patients (23 per group) and compares a single conventional stimulation with fresh embryo transfer on either Day 3 or Day 5 with an unconventional approach based on two oocyte retrievals and freeze-all of embryos on either Day 3 or Day 5, depending on the number and quality of the available embryos as decided by the embryologists. The protocol’s main novelty is that daily gonadotropin administration was not stopped after the trigger of ovulation in the first stimulation. Instead, it was continued until the day of trigger of the second ovulation. The authors concluded that double oocyte retrieval with continuous FSH administration did not increase the number of retrieved metaphase-II oocytes (primary outcome) compared to one conventional ovarian stimulation ( Boudry et al., 2024).


  • PGT-A IS WORTH IN WOMEN OLDER THAN 35 YEARS EVEN IF ONLY 1 OR 2 BLASTOCYSTS ARE OBTAINED. A PROPENSITY SCORE MATCHING STUDY

    by Alberto Vaiarelli, Danilo Cimadomo, Valentino Cimadomo, Laura Rienzi, Antonio Capalbo, Filippo Maria Ubaldi

  • Low-quality evidence from a randomized controlled trial due to an inappropriate IVF setting to challenge Dual Stimulation strategy

    by Filippo Maria Ubaldi, Alberto Vaiarelli, Danilo Cimadomo, Maria Cerrillo, Laura Rienzi, Juan A Garcia-Velasco

    Sir, We read with great interest the article ‘The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (Duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF’ by Massin et al. (2023). Although the authors conducted a randomized controlled trial (RCT) to compare (their) standard care approach with dual stimulation in the same ovarian cycle, their analysis is severely biased in our view and rather unfair with respect to the true value and need for this unconventional stimulation strategy. We summarized some considerations hereafter. First, with their study design, the authors are not only comparing two ovarian stimulation strategies but also two completely different settings such as fresh oocyte insemination versus oocyte accumulation via vitrification and fresh versus vitrified-warmed first embryo transfer strategy. Moreover, the study, limited in its sample size, is multicentric and the oocyte vitrification performance (cryo-survival rate: 81.6%) is below the benchmark value at reference centers. This is already a matter of concern; if the oocyte vitrification protocol per se is underperformed, it becomes subject to poorer outcomes after warming. Indeed, differences were reported by Massin et al. (2023) only in the dual stimulation arm between the two paired cohorts of oocytes, the first cohort being vitrified warmed (e.g. fertilization rate: 66.1%) and the second cohort being fresh (e.g. fertilization rate: 79.7%). Even more concerning, the implantation, cumulative positive heartbeat and live birth rates were all lower after dual stimulation (see Supplementary Figure S2 in Massin et al. (2023)), most probably because oocyte vitrification was performed exclusively in this study arm. Nevertheless, this impact was not statistically significant perhaps due to a limited sample size and the absence of data on the blastulation rates.


  • Open Access

    P-481 Additional sub-cutaneous progesterone: a putative strategy to counteract poor clinical outcomes after vitrified-warmed euploid blastocyst transfer?

    by E Trabucco, A Vaiarelli, A Sansone, P Petrone, D D Fasulo, D Cimadomo, P D’aLessandro, C Rucci, C Argento, R Carmelo, et al.

    Study question: Is there an association between additional subcutaneous progesterone (a-sP) during luteal phase support for vitrified-warmed euploid blastocyst transfers and the clinical outcomes? Summary answer: a-sP was mainly administered to worse-prognosis patients:positive-pregnancy-test (PPT), but also biochemical-pregnancy-loss (BPL) rates were lower than control, thereby involvingsimilar live-birth-rate (LBR) per transfer. What is known already: Frozen-embryo-transfer (FET) implementation is increasing worldwide, and luteal-phase-support is a hot-topic. Serum/uterine progesterone levels are key in eliciting immunological tolerance and uterine quiescence, while supporting the processes underlying embryo implantation. Yet, a consensus is missing on progesterone administration (formulation, route, dosage, and duration). Endometrial biopsy studies showed increased progesteroneconcentration after vaginal administration, while sP has excellent pharmacokinetics with faster peak serum concentration.Combining both administration routes might compensate cases ofpoor vaginal absorption and contribute to reaching adequate systemic/uterine levels. This synergy might be beneficial especially in RIF-patients, subject to lower LBRs also in the context of euploid ET. Study design, size, duration: Retrospective analysis of 775 vitrified-warmed euploid blastocysttransfers conducted January2020-March2021. Three of 12 gynecologists administrated a-sP as luteal phase support mostly to patients with a worse reproductive history (i.e., longer duration of infertility and/or higher number of previous failed IVF). We assessed the clinical outcomes (PPT, BPL, miscarriage and LBR) in the group of patients who used a-SP (N = 128) versus the control(N = 647), adjusting for confounders in logistic regression analyses. Participants/materials, setting, methods: Only euploid non-mosaic blastocysts were transferred. All patients had normal uterine cavities and thyroid function. Endometrial preparation was performed with either hormone-replacement-therapy (estradiol valerate 6mg/die plus vaginal micronized progesterone 800mg/die) or modified-natural-cycle (hCG administration plus vaginal micronized progesterone 400mg/die). In the a-sP group, the supplementation was started 3 days before FET. In case of pregnancy, the therapy was continued until the 8thweek. Main results and the role of chance: The patients in the control and a-sP groups were similar for oocyte age (37.6±2.7yr versus 37.5±2.7yr), age at ET (37.7±3.2yr versus 37.7±3.4yr), and body-mass-index (22.2±2.4 versus 22.0±2.8yr). Conversely, the patients in the a-SP group experienced longer duration of infertility (3.5±1.9yr in the control versus 4.1±2.6yr, p = 0.05), and had already undergone ≥1 previous IVF cycle (37%) and ≥2 failed ETs (22%) more frequently than the control (27% and 12%, respectively;p=0.05). The endometrial preparation protocol was similar in the two groups (76% hormone-replacement-therapy and 24% modified-natural-cycle). Also, blastocyst quality and day of transfer were similar. In the study period, the prevalence of a-sP administration increased from first to second-third ETs (13% to 29%). The confounders identified on the clinical outcomes were blastocyst quality, day of transfer and consecutive number of ET. Therefore, these features were included in multivariate logistic regressions. PPT rates were 61.1% (N = 395/647) and 49.2% (N = 63/128, p = 0.01) in the control and a-SP groups, respectively (multivariate-OR:0.65, 95%CI 0.44-0.97;adjusted-p=0.04). BPL rates were 9.1% (N = 36/395) and 1.6% (N = 1/63, p = 0.04), respectively (multivariate-OR:0.14, 95%CI 0.02-0.99;adjusted-p=0.05). Miscarriage rates were 14.2% (N = 51/359) and 6.5% (N = 4/62;p=0.1), respectively (multivariate-OR:0.4, 95%CI 0.14-1.16;adjusted-p=0.1). Lastly, LBRs were 47.6% (N = 308/647) and 45.3% (N = 58/128), respectively (multivariate-OR:1.04, 95% 0.7-1.55;adjusted-p=0.8). Limitations, reasons for caution: Retrospective analysis. Progesterone levels are not routinely assessed in our clinical practice. A larger prospective study only in poor prognosis patients is required to assess the putative benefit of a-sP. Wider implications of the findings: About 30% of patients undergoing FET suffer from inadequate progesterone levels, possibly impacting the clinical outcomes, yetscarcely detectable through its serum levels. In these women, vaginal progesterone could be insufficient, and a-sP can act as a rescue strategy against reduced endometrial receptivity via lower BPL. Trial registration number: Not applicable

  • Open Access

    The first mitotic division: a perilous bridge connecting the zygote and the early embryo

    by Giovanni Coticchio, Danilo Cimadomo, Greta Chiara Cermisoni, Laura Rienzi, Enrico Papaleo, Filippo Maria Ubaldi, Andrea Borini, Lucia De Santis

    Human embryos are very frequently affected by maternally inherited aneuploidies, which in the vast majority of cases determine developmental failure at pre- or post-implantation stages. However, recent evidence, generated by the alliance between diverse technologies now routinely employed in the IVF laboratory, has revealed a broader, more complex scenario. Aberrant patterns occurring at the cellular or molecular level can impact at multiple stages of the trajectory of development to blastocyst. In this context, fertilization is an extremely delicate phase, as it marks the transition between gametic and embryonic life. Centrosomes, essential for mitosis, are assembled ex novo from components of both parents. Very large and initially distant nuclei (the pronuclei) are brought together and positioned centrally. The overall cell arrangement is converted from being asymmetric to symmetric. The maternal and paternal chromosome sets, initially separate and scattered within their respective pronuclei, become clustered where the pronuclei juxtapose, to facilitate their assembly in the mitotic spindle. The meiotic spindle is replaced by a segregation machinery that may form as a transient or persistent dual mitotic spindle. Maternal proteins assist the decay of maternal mRNAs to allow the translation of newly synthesized zygotic transcripts. The diversity and complexity of these events, regulated in a precise temporal order and occurring in narrow time windows, make fertilization a highly error-prone process. As a consequence, at the first mitotic division, cellular or genomic integrity may be lost, with fatal consequences for embryonic development.


  • Open Access

    Towards Automation in IVF: Pre-Clinical Validation of a Deep Learning-Based Embryo Grading System during PGT-A Cycles

    by Danilo Cimadomo, Viviana Chiappetta, Federica Innocenti, Gaia Saturno, Marilena Taggi, Anabella Marconetto, Valentina Casciani, Laura Albricci, Roberta Maggiulli, Giovanni Coticchio, et al.

    Preimplantation genetic testing for aneuploidies (PGT-A) is arguably the most effective embryo selection strategy. Nevertheless, it requires greater workload, costs, and expertise. Therefore, a quest towards user-friendly, non-invasive strategies is ongoing. Although insufficient to replace PGT-A, embryo morphological evaluation is significantly associated with embryonic competence, but scarcely reproducible. Recently, artificial intelligence-powered analyses have been proposed to objectify and automate image evaluations. iDAScore v1.0 is a deep-learning model based on a 3D convolutional neural network trained on time-lapse videos from implanted and non-implanted blastocysts. It is a decision support system for ranking blastocysts without manual input. This retrospective, pre-clinical, external validation included 3604 blastocysts and 808 euploid transfers from 1232 cycles. All blastocysts were retrospectively assessed through the iDAScore v1.0; therefore, it did not influence embryologists’ decision-making process. iDAScore v1.0 was significantly associated with embryo morphology and competence, although AUCs for euploidy and live-birth prediction were 0.60 and 0.66, respectively, which is rather comparable to embryologists’ performance. Nevertheless, iDAScore v1.0 is objective and reproducible, while embryologists’ evaluations are not. In a retrospective simulation, iDAScore v1.0 would have ranked euploid blastocysts as top quality in 63% of cases with one or more euploid and aneuploid blastocysts, and it would have questioned embryologists’ ranking in 48% of cases with two or more euploid blastocysts and one or more live birth. Therefore, iDAScore v1.0 may objectify embryologists’ evaluations, but randomized controlled trials are required to assess its clinical value.


  • Open Access

    Multi- and Transgenerational Effects of Environmental Toxicants on Mammalian Reproduction

    by Paola Rebuzzini, Gemma Fabozzi, Danilo Cimadomo, Filippo Maria Ubaldi, Laura Rienzi, Maurizio Zuccotti, Silvia Garagna

    Environmental toxicants (ETs) are an exogenous chemical group diffused in the environment that contaminate food, water, air and soil, and through the food chain, they bioaccumulate into the organisms. In mammals, the exposure to ETs can affect both male and female fertility and their reproductive health through complex alterations that impact both gametogeneses, among other processes. In humans, direct exposure to ETs concurs to the declining of fertility, and its transmission across generations has been recently proposed. However, multi- and transgenerational inheritances of ET reprotoxicity have only been demonstrated in animals. Here, we review recent studies performed on laboratory model animals investigating the effects of ETs, such as BPA, phthalates, pesticides and persistent contaminants, on the reproductive system transmitted through generations. This includes multigenerational effects, where exposure to the compounds cannot be excluded, and transgenerational effects in unexposed animals. Additionally, we report on epigenetic mechanisms, such as DNA methylation, histone tails and noncoding RNAs, which may play a mechanistic role in a nongenetic transmission of environmental information exposure through the germline across generations.


  • How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence

    by Danilo Cimadomo, Daria Soscia, Valentina Casciani, Federica Innocenti, Samuele Trio, Viviana Chiappetta, Laura Albricci, Roberta Maggiulli, Itay Erlich, Assaf Ben-Meir, et al.

    STUDY QUESTION: What is the clinical value of Day 7 blastocysts? SUMMARY ANSWER: Ending embryo culture at 144 hours post-insemination (h.p.i.; i.e. 6 days) would involve 7.3% and 4.4% relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively. WHAT IS KNOWN ALREADY: Many studies showed that Day 7 blastocysts are clinically valuable, although less euploid and less competent than faster-growing embryos. Nevertheless, a large variability exists in: (i) the definition of ‘Day 7’; (ii) the criteria to culture embryos to Day 7; (iii) the clinical setting; (iv) the local regulation; and/or (v) the culture strategies and incubators. Here, we aimed to iron out these differences and portray Day 7 blastocysts with the lowest possible risk of bias. To this end, we have also adopted an artificial intelligence (AI)-powered software to automatize developmental timings annotations and standardize embryo morphological assessment. STUDY DESIGN, SIZE AND DURATION: Observational study including 1966 blastocysts obtained from 681 patients cultured in a time-lapse incubator between January 2013 and December 2020 at a private Italian IVF center. PARTICIPANTS/MATERIALS, SETTING, METHODS: According to Italian Law 40/2004, embryos were not selected based on their morphology and culture to ≥168 h.p.i. is standard care at our center. ICSI, continuous culture with Day 5 media refresh, trophectoderm biopsy without assisted hatching and comprehensive chromosome testing (CCT) to diagnose full-chromosome non-mosaic aneuploidies, were all performed. Blastocysts were clustered in six groups based on the time of biopsy in h.p.i. at 12 hr intervals starting from 168 h.p.i. Blastocyst quality was assessed using Gardner’s scheme and confirmed with AI-powered software. AI was also used to automatically annotate the time of expanding blastocyst (tEB) and the hours elapsing between this moment and the achievement of full expansion when blastocysts were biopsied and vitrified. Also, blastocyst area at tEB and at the time of biopsy was automatically assessed, as well as the hour of the working day when the procedure was performed. The main outcomes were the euploidy rate and the LB rate (LBR) per vitrified-warmed euploid single blastocyst transfer. The results were adjusted for confounders through multivariate logistic regressions. To increase their generalizability, the main outcomes were reported also based on a 144-h.p.i. cutoff (i.e. 6 exact days from ICSI). Based on this cutoff, all the main patient outcomes (i.e. number of patients obtaining blastocysts, euploid blastocysts, LBs, with supernumerary blastocysts without a LB and with surplus blastocysts after an LB) were also reported versus the standard care (>168 h.p.i.). All hypothetical relative reductions were calculated. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 14.6% of the blastocysts reached full expansion beyond 144 h.p.i. (5.9% in the range 144–156 h.p.i., 7.9% in the range 156–168 h.p.i. and 0.8% beyond 168 h.p.i.). Slower blastocysts were of a worse quality based on the evaluation of both embryologists and AI. Both later tEB and longer time between tEB and full blastocyst expansion concurred to Day 7 development, quite independently of blastocyst quality. Slower growing blastocysts were slightly larger than faster-growing ones at the time of biopsy, but no difference was reported in the risk of hatching, mainly because two dedicated slots have been set along the working day for these procedures. The lower euploidy rate among Day 7 blastocysts is due to their worse morphology and more advanced oocyte age, rather than to a slower development per se. Conversely, the lower LBR was significant even after adjusting for confounders, with a first relevant decrease for blastocysts biopsied in the range 132–144 h.p.i. (N = 76/208, 36.5% versus N = 114/215, 53.0% in the control, multivariate odds ratio 0.61, 95% CI 0.40–0.92, adjusted-P = 0.02), and a second step for blastocysts biopsied in the range 156–168 h.p.i. (N = 3/21, 14.3%, multivariate odds ratio: 0.24, 95% CI 0.07–0.88, adjusted-P = 0.03). Nevertheless, when the cutoff was set at 144 h.p.i., no significant difference was reported. In this patient population, ending embryo culture at 144 h.p.i. would have caused 10.6%, 7.3%, 4.4%, 13.7% and 5.2% relative reductions in the number of patients obtaining blastocysts, euploid blastocysts, LBs, supernumerary blastocysts without an LB and surplus blastocysts after an LB, respectively. LIMITATIONS, REASONS FOR CAUTION: Gestational and perinatal outcomes were not assessed, and a cost-effectiveness analysis is missing. Moreover, we encourage other groups to investigate this topic with different culture and biopsy protocols, as well as in different clinical settings and regulatory contexts. WIDER IMPLICATIONS OF THE FINDINGS: In view of the increasing personalization and patient-centeredness of IVF, whenever allowed from the local regulations, the choice to culture embryos to Day 7 should be grounded on the careful evaluation of couples’ reproductive history. Patients should be aware that Day 7 blastocysts are less competent than faster-growing ones; still, poor prognosis couples, couples less compliant toward other attempts in case of a failure and couples wishing for more than one child, may benefit from them. AI tools can help improving the generalizability of the evidence worldwide. STUDY FUNDING/COMPETING INTEREST(S): This study did not receive any funding. I.E., A.B.M. and I.H.-V. are employees of Fairtility Ltd. TRIAL REGISTRATION NUMBER: N/A.